The anti-HIV-1 action of JALEx could be possible by three synergistic effects: a) reactivation of HIV-1 from latency and its destruction by ART; b) blocking infection of new cells through down-modulation of CD4 on the lymphocyte surface; and c) by inducing the secretion of antiviral cytokines such as IL21. Here, IL21 is linked to infection.